Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors-Reference-Cited by-同舟云学术

Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors

Published:2021-12-28 Issue:1 Volume:65 Page:58-83
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Lu Xiaoyun¹^ORCID,Smaill Jeff B.²³,Patterson Adam V.²³,Ding Ke¹^ORCID

Affiliation:

1. School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China

2. Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, New Zealand

3. Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Private Bag 92019, Auckland, New Zealand

Funder

Health Research Council of New Zealand

Jinan University

National Natural Science Foundation of China

Cancer Society Auckland Northland

China Maurice Wilkins Centre Collaborative Research Program

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c01719

Reference110 articles.

1. The Protein Kinase Complement of the Human Genome

2. Kinase drug discovery 20 years after imatinib: progress and future directions

3. Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations

4. Structure-based design of targeted covalent inhibitors

5. Advances in covalent kinase inhibitors

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Covalent Inhibitors - An Overview of Design Process, Challenges and Future Directions;Current Organic Chemistry;2025-10

2. TopCysteineDB: A Cysteinome-wide Database Integrating Structural and Chemoproteomics Data for Cysteine Ligandability Prediction;Journal of Molecular Biology;2025-08

3. Unraveling the kinase code: Role of protein kinase in lung cancer pathogenesis and therapeutic strategies;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2025-07

4. Optimization of Aminoindazole derivatives as highly selective covalent inhibitors for wild-type and mutant FGFR4;Bioorganic Chemistry;2025-06

5. Tumor microenvironment-responsive self-assembled nanomedicine for reversible covalent targeting of BCR-ABL kinase;Chinese Chemical Letters;2025-06